Company Overview and News

 
Screening The Canadian Market For The #1 Dividend Growth Utility Stock

2018-05-22 seekingalpha
In this article, we'll review all utilities in Canada that have increased their dividend for 5 or more years in a row and apply a dividend growth screen to try and find the best high-quality utility companies for further consideration. Turns out there was only one company that passed all of the criteria, but there are still a few other companies that are worthy of your consideration.

 
155 Monthly Pay SML Equities Show 1.85% To 17.92% Yields And 70 Funds Yield 7.16% To 19.5%

2018-05-21 seekingalpha
Here's your April 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Reports. Nano-Cap MoPays are not listed.

 
TransAlta's (TAC) CEO Dawn Farrell on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good morning. My name is Chris, and I will be your conference operator today. At this time, I would like to welcome everyone to the TransAlta Corporation First Quarter Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question-and-answer session. [Operator Instructions] Thank you.

1
128 Monthly Pay Small/Mid/Large Cap Equities Show 3.6%-17.52% Yields; 62 Funds Yield 6.15%-19.5%

2018-04-16 seekingalpha
Contents: 1. US/CDN Stocks @3.58%+ yield (128) 2. Stocks by price upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds & Notes (CEICs/ETFs/ETNs) @6.15%+ yield (62).

 
The Whole Is Greater Than Its Parts

2018-03-06 seekingalpha
They agree on many things, including the importance of being macro-oriented and using options strategies as a hedge against risk and to enhance returns.

 
TransAlta's (TAC) CEO Dawn Farrell on Q4 2017 Results - Earnings Call Transcript

2018-03-03 seekingalpha
Good morning ladies and gentlemen, thank you for standing by. Welcome to the TransAlta Corporation Fourth Quarter and Full Year 2017 Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be question-and-answer session. [Operator Instructions] As a reminder, this conference call is being broadcast live on the internet and recorded.

 
BRIEF-Transalta Renewables Acquires Two U.S. Wind Projects

2018-02-20 reuters
* TRANSALTA RENEWABLES INC - ‍TOTAL COST OF 2 PROJECTS IS ESTIMATED TO BE $240 MILLION, OF WHICH APPROXIMATELY 70% WILL BE FUNDED IN 2018, REMAINDER IN 2019​

1
Should You Buy This 7% Yielding Utility Company?

2018-01-12 seekingalpha
TransAlta Renewable has a diversified portfolio of clean and renewable power generators in Canada, the U.S. and Australia Killam’s.

3
Dividend Sensei Positions For 2018: Something Is Always On Sale

2018-01-03 seekingalpha
My goal is to generate maximum safe yield, with fast dividend growth, and buy stocks at their most undervalued.

 
'Safer' Dividend S-M-L MoPay Gains Are By 6 REITS, 2 Financials, 1 Health, 1 Utility To 12/19/18

2017-12-22 seekingalpha
32 of 106 Monthly Paying (MoPay) Small-Mid-Large Cap US & Canadian Dividend stocks were tagged "safer" by showing positive annual-returns, and free cash-flow-yields greater than their dividend-yields as of 12/19/17.

1
Dividend Sensei's Portfolio Update 14: Want To Retire Rich? Then Choose Your Next Car Carefully

2017-12-19 seekingalpha
My sister's new used car is a great example of how becoming rich isn't just luck, but includes important lifestyle choices.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 893463109